MedTrace Logo

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

NCT04260256 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-03-27

No results posted yet for this study

Summary

In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.

Conditions

  • Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit

Interventions

DRUG

[18F]F-AraG

\[18F\]F AraG injection and PET Scan Two tumor biopsies of single lesion

Sponsors & Collaborators

  • Stanford University

    collaborator OTHER

  • Oregon Health and Science University

    collaborator OTHER

  • CellSight Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Carina Mari Aparici, M.D. · Stanford University

  • Erik Mittra, M.D. · Oregon Health and Science University

  • Shivaani Kummar, M.D. · Oregon Health and Science University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2026-03-01
Completion
2026-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04260256 on ClinicalTrials.gov